Dilemmas in commissioning biological therapies

Editorial discusses what approach commissioning organisations should take when changes to clinical practice/market authorisation have a significant impact on how biologics can be used. It calls for development of a national process to facilitate a rapid response to such changes.

Drug and Therapeutics Bulletin